Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion
Novel adjuvant strategies are needed to optimize outcomes after complete surgical resection in patients with early-stage non-small-cell lung cancer (NSCLC). The adjuvant treatment of ROS Proto-Oncogene 1 (ROS1) fusion-positive resected NSCLC is challenging because there is no curative confirmed rand...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.837219/full |
| _version_ | 1819005952428343296 |
|---|---|
| author | An-guo Chen Dong-sheng Chen Dong-sheng Chen Dong-sheng Chen Si Li Si Li Si Li Le-le Zhao Le-le Zhao Le-le Zhao Ming-zhe Xiao Ming-zhe Xiao Ming-zhe Xiao |
| author_facet | An-guo Chen Dong-sheng Chen Dong-sheng Chen Dong-sheng Chen Si Li Si Li Si Li Le-le Zhao Le-le Zhao Le-le Zhao Ming-zhe Xiao Ming-zhe Xiao Ming-zhe Xiao |
| author_sort | An-guo Chen |
| collection | DOAJ |
| description | Novel adjuvant strategies are needed to optimize outcomes after complete surgical resection in patients with early-stage non-small-cell lung cancer (NSCLC). The adjuvant treatment of ROS Proto-Oncogene 1 (ROS1) fusion-positive resected NSCLC is challenging because there is no curative confirmed randomized controlled trial. Next-generation sequencing (NGS) and immunohistochemistry (IHC) staining were performed on the biopsy sample. In this case, we identified a novel LDLR–ROS1 fusion in a resectable stage IIIA NSCLC patient. The patient received crizotinib as adjuvant treatment and achieved recurrence-free survival (RFS) for 29 months, without significant symptoms of toxicity. In this case, we report a novel LDLR–ROS1 fusion responding to crizotinib in a patient with lung adenocarcinoma, supporting the use of adjuvant treatment with the ROS1 inhibitor exerting clinical survival benefit in ROS1 fusion-positive resected NSCLC. |
| first_indexed | 2024-12-21T00:00:58Z |
| format | Article |
| id | doaj.art-1edd8d77d09b40fdad59a45edff5b622 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-21T00:00:58Z |
| publishDate | 2022-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-1edd8d77d09b40fdad59a45edff5b6222022-12-21T19:22:36ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-03-011210.3389/fonc.2022.837219837219Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 FusionAn-guo Chen0Dong-sheng Chen1Dong-sheng Chen2Dong-sheng Chen3Si Li4Si Li5Si Li6Le-le Zhao7Le-le Zhao8Le-le Zhao9Ming-zhe Xiao10Ming-zhe Xiao11Ming-zhe Xiao12Department of Thoracic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaThe Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, ChinaNanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, ChinaThe State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, ChinaThe Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, ChinaNanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, ChinaThe State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, ChinaThe Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, ChinaNanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, ChinaThe State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, ChinaThe Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, ChinaNanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, ChinaThe State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, ChinaNovel adjuvant strategies are needed to optimize outcomes after complete surgical resection in patients with early-stage non-small-cell lung cancer (NSCLC). The adjuvant treatment of ROS Proto-Oncogene 1 (ROS1) fusion-positive resected NSCLC is challenging because there is no curative confirmed randomized controlled trial. Next-generation sequencing (NGS) and immunohistochemistry (IHC) staining were performed on the biopsy sample. In this case, we identified a novel LDLR–ROS1 fusion in a resectable stage IIIA NSCLC patient. The patient received crizotinib as adjuvant treatment and achieved recurrence-free survival (RFS) for 29 months, without significant symptoms of toxicity. In this case, we report a novel LDLR–ROS1 fusion responding to crizotinib in a patient with lung adenocarcinoma, supporting the use of adjuvant treatment with the ROS1 inhibitor exerting clinical survival benefit in ROS1 fusion-positive resected NSCLC.https://www.frontiersin.org/articles/10.3389/fonc.2022.837219/fullROS1 fusioncrizotinibadjuvant treatmentNSCLCcase report |
| spellingShingle | An-guo Chen Dong-sheng Chen Dong-sheng Chen Dong-sheng Chen Si Li Si Li Si Li Le-le Zhao Le-le Zhao Le-le Zhao Ming-zhe Xiao Ming-zhe Xiao Ming-zhe Xiao Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion Frontiers in Oncology ROS1 fusion crizotinib adjuvant treatment NSCLC case report |
| title | Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion |
| title_full | Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion |
| title_fullStr | Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion |
| title_full_unstemmed | Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion |
| title_short | Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion |
| title_sort | case report adjuvant crizotinib therapy exerted favorable survival benefit in a resectable stage iiia nsclc patient with novel ldlr ros1 fusion |
| topic | ROS1 fusion crizotinib adjuvant treatment NSCLC case report |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.837219/full |
| work_keys_str_mv | AT anguochen casereportadjuvantcrizotinibtherapyexertedfavorablesurvivalbenefitinaresectablestageiiiansclcpatientwithnovelldlrros1fusion AT dongshengchen casereportadjuvantcrizotinibtherapyexertedfavorablesurvivalbenefitinaresectablestageiiiansclcpatientwithnovelldlrros1fusion AT dongshengchen casereportadjuvantcrizotinibtherapyexertedfavorablesurvivalbenefitinaresectablestageiiiansclcpatientwithnovelldlrros1fusion AT dongshengchen casereportadjuvantcrizotinibtherapyexertedfavorablesurvivalbenefitinaresectablestageiiiansclcpatientwithnovelldlrros1fusion AT sili casereportadjuvantcrizotinibtherapyexertedfavorablesurvivalbenefitinaresectablestageiiiansclcpatientwithnovelldlrros1fusion AT sili casereportadjuvantcrizotinibtherapyexertedfavorablesurvivalbenefitinaresectablestageiiiansclcpatientwithnovelldlrros1fusion AT sili casereportadjuvantcrizotinibtherapyexertedfavorablesurvivalbenefitinaresectablestageiiiansclcpatientwithnovelldlrros1fusion AT lelezhao casereportadjuvantcrizotinibtherapyexertedfavorablesurvivalbenefitinaresectablestageiiiansclcpatientwithnovelldlrros1fusion AT lelezhao casereportadjuvantcrizotinibtherapyexertedfavorablesurvivalbenefitinaresectablestageiiiansclcpatientwithnovelldlrros1fusion AT lelezhao casereportadjuvantcrizotinibtherapyexertedfavorablesurvivalbenefitinaresectablestageiiiansclcpatientwithnovelldlrros1fusion AT mingzhexiao casereportadjuvantcrizotinibtherapyexertedfavorablesurvivalbenefitinaresectablestageiiiansclcpatientwithnovelldlrros1fusion AT mingzhexiao casereportadjuvantcrizotinibtherapyexertedfavorablesurvivalbenefitinaresectablestageiiiansclcpatientwithnovelldlrros1fusion AT mingzhexiao casereportadjuvantcrizotinibtherapyexertedfavorablesurvivalbenefitinaresectablestageiiiansclcpatientwithnovelldlrros1fusion |